About
Financing
Partners
Public Deliverables
About
Governance
Research
CLARA Testbed
Selected Publications
Joint Projects
Theme Development Meetings
Other IPRs
Access to Infrastructure
AI services
CLARA Collaboratorium
Business Acceleration
Ethics & AI Compliance
Grant Office
Our Approach
Pilot Use-Case
Research Programs
Scientific Environment
Theme Development Meetings
Training Program
CLARA Testbed
Core facilities
CLARA Collaboratorium
Career
CLARA Young Innovator Award
Grant Office
All Articles
Press releases
Events

Our Approach

Business Acceleration

Business Acceleration

At CLARA, we bridge the gap between cutting-edge scientific discovery and real-world commercial application. Our business acceleration framework is designed to transform breakthroughs in AI, HPC/quantum computing, and neuroscience into scalable solutions that benefit patients, industry, and society.

The VentureLab Ecosystem

Our primary engine for business acceleration is VentureLab, a dedicated deep-tech incubator established as a joint venture between INDRC/CLARA, research partners, and private sector experts (IPL Ventures). Unlike traditional accelerators, VentureLab is tailored for "Tough Tech" projects with high capital requirements and often long development cycles. VentureLab collaborates with an independent deep tech VC fund focused on pre-seed and seed financing (up to €1M per project), ensuring our most promising innovations have the capital to scale.

Commercialization Roadmap

We follow a structured pathway to ensure our Key Exploitable Results (KERs) achieve maximum market impact. We guide spinoutsfrom the lab to the market through commercial validation, IP hardening, interim management, and project coordination, esp.:

  • Identification & Protection: Utilizing the Innovation Radar methodology to assess and manage innovation potential, maturity, and market readiness before and after protection.
  • Licensing & Spin-offs: We offer flexible models ranging from open-source licensing for research communities to exclusive licensing and full spin-off creation for commercial ventures.
  • Grant Lab Integration: Our Grant Lab acts as a strategic accelerator for funding, not just for research but for commercial pilots.

Join us in building the future of brain health. Whether you are an investor, a pharmaceutical partner, or a researcher with a disruptive idea, CLARA provides the ecosystem to turn your vision into reality.

1

Quantum-Accelerated Protein Dynamics:

We develop advanced foundation models to simulate protein dynamics and aggregation involved in neurodegenerative diseases. By harnessing quantum computing power, we can explore molecular mechanisms at unprecedented scales, opening new avenues for drug discovery.

2

AI-Driven Clinical Phenomenology:

Our team creates generative AI models that integrate diverse data types, from molecular to clinical, to understand the complex progression of Alzheimer's disease over decades. This approach aims to revolutionize patient care through precision medicine tools.

3

Multiscale Brain Modeling:

We are building a first-of-its-kind integrated knowledge platform that allows exploration across various spatial and temporal levels of brain organization. This innovative tool will provide crucial insights into the intricate connections between biological factors and clinical symptoms.

The CLARA Advantage

By combining these research streams with our state-of-the-art CLARA Testbed infrastructure, we are uniquely positioned to:

Accelerate the discovery of new intervention targets for neurodegenerative diseases

Develop more accurate predictive models for disease progression

Identify personalized therapeutic approaches for patients

Bridge the gap between molecular processes and clinical outcomes

Our interdisciplinary team of experts from neuroscience, artificial intelligence, quantum computing, and clinical research is committed to pushing the boundaries of brain research. Together, we aim to unravel the mysteries of neuronal longevity and vitality, paving the way for groundbreaking advancements in the fight against neurodegenerative diseases.